Nav: Home

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia

July 31, 2020

Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply. A tyrosine kinase inhibitor (TKI) is a medication given to certain acute myeloid leukemia (AML) patients to block the actions of overactive tyrosine kinases, with the ultimate goal of stopping or slowing cancer cell growth. In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute (HCI) researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah (U of U), showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death. Patel and colleagues believe this study helps to outline a potential new treatment approach in AML patients who have a mutation in a gene called FLT3.

AML is a type of blood cancer that affects white blood cells in the body. About 30% of all AML patients have a mutation in a tyrosine kinase called FLT3. This protein sits on the surface of blood cells and binds to a specific molecule called FL outside the cell. Normally, binding of FL activates the FLT3 receptor and causes cell growth. However, when mutations occur in FLT3 growth signals are sent to leukemia cells even when FL is not present. Quizartinib is a type of FLT3 inhibitor that was developed for AML patients with FLT3 mutations.

AML patients respond well to quizartinib initially, but usually their disease returns shortly after treatment. "It is amazing to see how small molecule inhibitors have transformed cancer care for so many leukemia patients," said Patel. "However, the sobering reality is that even new and exciting drugs often only work to control leukemia for a finite period of time before the patient develops drug resistance and relapses."

Using blood and marrow samples donated by AML patients at HCI, Patel found that factors produced by bone marrow support cells are taken up by leukemia cells, activating survival pathways that protect leukemia cells from being killed by quizartinib. One of the signaling pathways activated in leukemia cells was the STAT5 pathway. Patel also found that these bone marrow factors speed up energy production in leukemia cells, allowing for cancer cell survival. Treating leukemia cells with a combination of quizartinib and dasatinib overcame the protective effects from bone marrow support cells in this laboratory study and killed leukemia cells more effectively than quizartinib alone.

Patel plans to use these findings to support future studies of resistance to TKIs in another type of leukemia called chronic myelomonocytic leukemia. Collectively, insights from these studies will be used to develop clinical trials to improve treatment options for leukemia patients.
This study was supported by the National Institutes of Health including the National Cancer Institute (NCI) P30 CA042014, R21 CA20593601, R01 CA178397, the American Society of Hematology Research Training Award for Fellows, the V Foundation for Cancer Research translational research grant T2017-008, and Huntsman Cancer Foundation.

Huntsman Cancer Institute

Related Acute Myeloid Leukemia Articles:

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease.
Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.
Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.
SIRT1 plays key role in chronic myeloid leukemia to aid persistence of leukemic stem cells
Patients with chronic myeloid leukemia are treated with tyrosine kinase inhibitors.
Gilteritinib improved survival for patients with acute myeloid leukemia
Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from the ADMIRAL phase III clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
New treatment of acute myeloid leukemia achieves remarkable results in a disease formerly with little hope
A new Australian drug trial has achieved a remarkable result, clearing the bone marrow of leukemia in almost 60 percent of patients.
Epigenetic protein could be new therapeutic target in acute myeloid leukemia
British researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth.
Atlas of acute myeloid leukemia cell types may lead to improved, targeted therapies
A research team led by Massachusetts General Hospital investigators has assembled a detailed atlas of bone marrow cells from patients with acute myeloid leukemia, an aggressive blood cancer that usually leads to death within five years of diagnosis.
Potential seen for tailoring treatment for acute myeloid leukemia
Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia.
Solving the mystery of NPM1 in acute myeloid leukemia
Acute myeloid leukemia (AML) cells expressing the NPM1 mutant gene are highly dependent on continued export of protein NPM1c to proliferate.
More Acute Myeloid Leukemia News and Acute Myeloid Leukemia Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at